Drug Profile
Dorzagliatin - Hua Medicine
Alternative Names: Doglietin; doxagliestatin; Doxgliatine; HMS-5552; HuaTangNing; RO-5305552; SinogliatinLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Hua Medicine
- Class Acetamides; Antihyperglycaemics; Chlorobenzenes; Phenyl ethers; Pyrazoles; Pyrroles; Small molecules
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies; Type 2 diabetes mellitus
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 27 Nov 2023 Launched for Diabetic nephropathies (Combination therapy) in China (PO) (Hua Medicine pipeline, November 2023)
- 27 Nov 2023 Launched for Diabetic nephropathies in China (PO) (Hua Medicine pipeline, November 2023)
- 23 Jun 2023 Efficacy data from a phase I trial in Type 2 diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023)